FDA publishes 29 new and revised generic drug guidances, bringing its 2026 total to 268, with updated bioequivalence recommendations for complex generics.
Written By: Umesh Hanumante, M. Pharm (RA)
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) published 29 new and revised draft product-specific guidances (PSGs) on November 20, 2026, providing updated recommendations for developing generic versions of recently approved drugs and established medicines. The latest batch includes 15 new and 14 revised guidances, covering complex products and alternative bioequivalence approaches for ophthalmic and topical formulations. The publication brings the agency’s total PSG output for 2026 to 268.
New Guidances Cover Recently Approved Drugs
The latest publication includes 15 new PSGs covering products for which generic developers need product-specific regulatory recommendations. These include orforglipron calcium (Foundayo; NDA 220934), an oral GLP-1 receptor agonist for obesity and weight management; nerandomilast (Jascayd; NDA 218764), indicated for idiopathic pulmonary fibrosis; and zongertinib (Hernexeos; NDA 219042), an oral tyrosine kinase inhibitor for HER2-mutant non-small cell lung cancer.
These recommendations provide generic developers with an initial regulatory framework for establishing therapeutic equivalence to the respective reference listed drugs (RLDs). Other newly covered products include aficamten, imlunestrant tosylate, remibrutinib, paltusotine hydrochloride and delgocitinib.
Of the 29 guidances, 24 address products without approved abbreviated new drug applications (ANDAs), including nine complex products. The overall batch contains 11 complex-product guidances, comprising four new and seven revised recommendations.
Revised Bioequivalence Approaches Address Complex Formulations
Two revisions highlight FDA’s continued use of formulation characterization and in vitro testing to support generic development.
The revised guidance for betaxolol hydrochloride ophthalmic suspension (BETOPTIC S; NDA 019845) introduces an in vitro bioequivalence pathway for the 0.25% formulation. Applicants using this approach must demonstrate qualitative (Q1) sameness, meaning the same inactive ingredients as the reference product, and quantitative (Q2) sameness, with inactive ingredient concentrations within ±5% of those in the reference product. The recommended studies include particle-size distribution analysis and comparative in vitro release testing (IVRT), supported by physicochemical characterization. Applicants can alternatively conduct a comparative clinical endpoint bioequivalence study.
For trifarotene 0.005% topical cream (AKLIEF; NDA 211527), FDA adds a characterization-based approach as an alternative to a comparative clinical endpoint study. The recommended pathway combines comparative physicochemical and structural characterization (Q3), IVRT and in vitro permeation testing (IVPT). The approach requires adequate formulation similarity, with no differences in inactive ingredients or other characteristics that could significantly affect local or systemic drug availability.
FDA also notes that it does not yet have sufficient empirical IVPT data for trifarotene using the recommended approach. The agency encourages applicants to seek regulatory feedback through pre-ANDA product development meetings when necessary.
Both revisions reflect the contribution of Generic Drug User Fee Amendments (GDUFA)-funded research to developing scientifically supported alternatives to conventional clinical bioequivalence studies.
Implications for Generic Drug Development
PSGs provide product-specific recommendations on the evidence needed to demonstrate bioequivalence and therapeutic equivalence to an RLD. Depending on the formulation, these recommendations may include in vivo or in vitro studies, dissolution testing, physicochemical characterization and applicable study waivers.
For complex generics, clearer testing pathways can reduce uncertainty during formulation development, help developers allocate research resources and support more complete ANDA submissions. Under GDUFA III, applicants can also request PSG teleconferences and pre- or post-submission meetings to discuss the potential impact of revised recommendations on their development programmes.
However, publication of a draft PSG does not guarantee generic approval or remove the need to meet applicable regulatory requirements.
Public Comments and Next Regulatory Steps
FDA will consider industry and public feedback before finalizing the draft recommendations. The Federal Register notice identifies January 19, 2027, as the deadline for submitting comments under docket FDA-2007-D-0369.
The agency also updated its upcoming PSG publication schedule, providing information on planned new and revised guidances, revision categories and projected publication dates.
The latest action advances FDA’s broader generic drug competition objectives under the Drug Competition Action Plan and Executive Order 14273, while GDUFA III supports the scientific and regulatory framework for generic drug development. Continued expansion of product-specific recommendations, particularly for complex formulations, could improve development predictability and support future generic competition across additional therapeutic areas.
References
FDA Publishes New Batch of Product-Specific Guidances to Facilitate Generic Drug Development, US FDA, 19 November 2026
Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability, Federal Register, US FDA, 20 November 2026
Product-Specific Guidances for Generic Drug Development, US FDA, 28 August 2026
Upcoming Product-Specific Guidances for Generic Drug Product Development, US FDA, 19 November 2026
GDUFA III Enhancements to the Pre-ANDA Program, US FDA, 22 July 2026
Draft Guidance on Betaxolol Hydrochloride, US FDA, November 2026
Draft Guidance on Trifarotene, US FDA, November 2026
Drug Competition Action Plan, US FDA
Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First, The White House, 15 April 2025
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.


